

## UNITED STATE DEPARTMENT OF COMMERCE

Pat nt and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

FIRST NAMED INVENTOR APPLICATION NO. FILING DATE ATTORNEY DOCKET NO. 09/444,067 11/19/99 MURPHY В 17634-000512 **EXAMINER** 020350 HM12/0414 TOWNSEND AND TOWNSEND AND CREW LLP BRUMBACK, B TWO EMBARCADERO CENTER ART UNIT PAPER NUMBER EIGHTH FLOOR SAN FRANCISCO CA 94111 1642 DATE MAILED: 04/14/00

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

## Office Action Summary

Application No. 09/444,067

Applicant(s)

Examiner

Brenda Brumback

Murphy et al. Group Art Unit

1642



Responsive to communication(s) filed on	
☐ This action is FINAL.	
☐ Since this application is in condition for allowance except for formal main accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11;	
A shortened statutory period for response to this action is set to expire is longer, from the mailing date of this communication. Failure to respond application to become abandoned. (35 U.S.C. § 133). Extensions of time 37 CFR 1.136(a).	within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	is/are allowed.
☐ Claim(s)	is/are rejected.
Claim(s)	is/are objected to.
	subject to restriction or election requirement.
Application Papers  See the attached Notice of Draftsperson's Patent Drawing Review, Interpolation is filed on is/are objected to by the proposed drawing correction, filed on is The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign priority under 35 to All Some* None of the CERTIFIED copies of the priority received.  received in Application No. (Series Code/Serial Number)	he Examiner.  _approved _disapproved.   U.S.C. § 119(a)-(d).  ity documents have been
received in this national stage application from the Internation	
*Certified copies not received:  Acknowledgement is made of a claim for domestic priority under 35	
	0 0.0.0. 3 1 10(0).
Attachment(s)  Notice of References Cited, PTO-892  Information Disclosure Statement(s), PTO-1449, Paper No(s).  Interview Summary, PTO-413  Notice of Draftsperson's Patent Drawing Review, PTO-948  Notice of Informal Patent Application, PTO-152	·
SEE OFFICE ACTION ON THE FOLLO	NUMC DAGES

Application/Control Number: 09/444,067

Art Unit: 1642

## **DETAILED ACTION**

## Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-10, 47-51, and 61, drawn to recombinant respiratory syncytial viruses (RSV) with temperature sensitive amino acid substitutions and methods of making recombinant RSV, classified in class 435, subclass 235.1.
  - II. Claims 1, 11-14, 26-28, and 47-53 drawn to recombinant RSV with a modified SH gene, classified in class 435, subclass 235.1.
  - III. Claims 1, 11, 20, 31-34, 47-51, 54, 56-58, 61, and 62 drawn to recombinant RSV with heterologous RSV genes, classified in class 424, subclass 199.1.
  - IV. Claims 1, 21, 26, 35, 47-51, and 59 drawn to recombinant RSV with genome modifications to encode non-RSV proteins, classified in class 424, subclass 199.1.
  - V. Claims 1, 11, and 19, drawn to recombinant RSV with a nucleotide modification in a translational start codon, classified in class 435 subclass 235.1.
  - VI. Claims 1, 11, 18 and 38, drawn to recombinant RSV with a nucleotide modification in a termination codon or a GS or GE transcription signal, classified in class 435, subclass 235.1.
  - VII. Claims 1, 11, 22-25, 30, 36, 37, 47-51, 54, 55, and 60, drawn to recombinant RSV with a parainfluenza (PIV) gene classified in class 424, subclass 199.1.

Application/Control Number: 09/444,067

Art Unit: 1642

- VIII. Claims 1, 11, 15-17, 29, 30, 47-51, 54, and 55 drawn to recombinant RSV with a nucleotide modification to a cis-acting regulatory sequence classified in class 435, subclass 235.1.
- IX. Claims 1, 26, and 38-46, drawn to a vaccine and methods of stimulating the immune system, classified in class 424, subclass 211.1.
- 2. The inventions are distinct, each from the other because of the following reasons:

  The products of Groups I-VIII have different structures and different characteristics.

Inventions I, IV, VI and IX are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the viruses of Groups I, IV, and VI can be used in the materially different process of diagnostic testing.

It is noted that claims 1, 11, 26, 30, 38, 47-51, 54, 55, and 61 are included in more than a single group. These claims will be examined with the elected group to the extent that they read on that group.

Application/Control Number: 09/444,067

Art Unit: 1642

- 3. Because these inventions are distinct for the reasons given above and the search required for each of the groups is not required for the other groups, restriction for examination purposes as indicated is proper.
- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda Brumback whose telephone number is (703) 306-3220. If the examiner can not be reached, inquiries can be directed to Supervisory Patent Examiner Anthony Caputa whose telephone number is (703) 308-3995. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Examiner Brenda Brumback, Art Unit 1642 and should be marked "OFFICIAL" for entry into prosecution history or "DRAFT" for consideration by the examiner without entry. The Art Unit 1642 FAX telephone number is (703)-305-3014. FAX machines will be available to receive transmissions 24 hours a day. In compliance with 1096 OG 30, the filing date accorded to each OFFICIAL fax transmission will be determined by the

Art Unit: 1642

FAX machine's stamped date found on the last page of the transmission, unless that date is a Saturday, Sunday or Federal Holiday with the District of Columbia, in which case the OFFICIAL date of receipt will be the next business day.

BB

April 13, 2000

Brenda Brumback,

Patent Examiner